Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluation of Innate and Adaptive Immune Responses to the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccine: Insights from an Ancillary Study of the EBL2001 Phase 2 Trial

  • By

  • Christine Lacabaratz

  • Mélany Durand

  • Aurélie Wiedemann

  • Emile Foucat

  • Mathieu Surénaud

  • Corinne Krief

  • Lydia Guillaumat

  • Cynthia Robinson

  • Kerstin Luhn

  • Viki Bockstal

  • Rodolphe Thiébaut

  • Laura Richert

  • Yves Lévy

  • July 16, 2024

Share

Original Source(s)

Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial

  • by Christine Lacabaratz, Mélany Durand, Aurélie Wiedemann, Emile Foucat, Mathieu Surénaud, Corinne Krief, Lydia Guillaumat, Cynthia Robinson, Kerstin Luhn, Viki Bockstal, Rodolphe Thiébaut, Laura Richert, Yves Lévy

  • July 16, 2024

Related Content

Congo Ebola Outbreak Strains Care Delivery

“We live with fear in our stomachs"

Top 10 evidence-based essentials in infectious disease

A structured framework of guidelines, trials, therapies, and tools used in clinical practice

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness